摘要
目的:探索阿柏西普玻璃体注射联合577 nm微脉冲激光治疗糖尿病性黄斑水肿(DME)的效果。方法:选取2020年1-4月于江西医学高等专科学校第一附属医院眼科就诊的DME患者60例(68眼),通过随机数字表法分为观察组和对照组,每组30例(34眼)。对照仅给予阿柏西普玻璃体注射治疗,观察组在对照组的基础上联合577 nm微脉冲激光治疗,两组均连续治疗3个月,并每月随访至满一年。比较两组临床疗效、最佳矫正视力(BCVA)、黄斑中心区视网膜厚度(CMT)、阿柏西普注射次数及并发症情况。结果:观察组临床总有效率为97.06%,明显高于对照组的79.41%(P<0.05)。治疗后,两组BCVA均高于治疗前,CMT均低于治疗前,且观察组BCVA高于对照组,CMT低于对照组,差异均有统计学意义(P<0.05)。观察组阿柏西普注射次数少于对照组(P<0.05)。两组并发症发生率比较,差异无统计学意义(P>0.05)。结论:阿柏西普玻璃体注射联合577 nm微脉冲激光治疗DME的临床效果显著,可明显改善患者视力情况、降低黄斑区水肿情况,减少阿柏西普的注射次数,同时并未导致并发症发生率的增加。
Objective:To explore the clinical effect of Aflibercept vitreous injection combined with 577 nm micropulse laser in the treatment of diabetic macular edema (DME).Method:A total of 60 patients (68 eyes)with DME who attended the Department of Ophthalmology of the First Affiliated Hospital of Jiangxi Medical College from January 2020 to April 2020 were selected,and they were divided into the observation group and the control group by random number table,30 cases (34 eyes) in each group.The control group was only given Aflibercept injection treatment,and the observation group was treated with 577 nm micropulse laser on the basis of the control group.Two groups were treated for 3 months continuously and followed up every month for one year.The clinical efficacy,best cor-rected vision acuity (BCVA),central macular thickness (CMT),the injections number of Aflibercept and complications of two groups were compared.Result:The total clinical effective rate of the observation group was 97.06%,which was significantly higher than 79.41% of the control group (P<0.05).The BCVA of two groups after treatment were significantly higher than those before treatment,and the CMT were significantly lower than before treatment,the BCVA in the observation group was significantly higher than that in the control group,and the CMT was significantly lower than that in the control group,the differences were statistically significant (P<0.05).The injections number of Aflibercept in the observation group was significantly less than that in the control group (P<0.05).There was no significant difference in the incidence of complications between two groups (P>0.05).Conclusion:The clinical efficacy of Aflibercept vitreous injection combined with 577 nm micropulse laser in the treatment of DME is significant,it can significantly improve the patient’s vision,reduce macular edema,the injections number of Aflibercept,without causing complications increasing incidence of disease.
作者
毛羽佳
杨媛媛
殷俏
郑琳璐
MAO Yujia;YANG Yuanyuan;YIN Qiao;ZHENG Linlu(The First Affiliated Hospital of Jiangxi Medical College,Shangrao 334000,China;不详)
出处
《中国医学创新》
CAS
2022年第14期108-112,共5页
Medical Innovation of China
基金
江西省卫健委项目(202141027)。
